Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Rheumatology and Arthritis Learning Network or HMP Global, their employees, and affiliates.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
Researchers aimed to evaluate how achieving different levels of clinical response or disease activity in patients with nonradiographic (nr-) and radiographic (r-) axial spondyloarthritis.
Researchers aimed to evaluate how achieving different levels of clinical response or disease activity in patients with nonradiographic (nr-) and radiographic (r-) axial spondyloarthritis.